Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eshani Karu

General Practice Pomona, CA Medical Doctor

NPI 1982177622 CMS profile 5776814

1900 Royalty Dr Ste 250, Pomona, CA 91767

Open in the dashboard

General payments

$9,455

329 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eshani Karu of Pomona, CA is reported in the CMS Open Payments database as having received $9,455 across 329 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $337 6
2024 General $563 11
2023 General $1,715 41
2022 General $2,280 59
2021 General $1,715 86
2020 General $1,331 70
2019 General $1,514 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eshani Karu
  • General Practice median
  • Middle half of General Practice
  • National median

In program year 2025, general payments to Eshani Karu were reported at $337. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.

Show as a table
Year Eshani Karu General Practice median Middle half National median
2019 $1,514 $107 $37–$285 $163
2020 $1,331 $75 $25–$213 $114
2021 $1,715 $93 $30–$272 $132
2022 $2,280 $103 $36–$279 $149
2023 $1,715 $106 $34–$276 $160
2024 $563 $114 $39–$290 $164
2025 $337 $106 $35–$292 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,045 26 payments
  2. Amgen Inc. $1,035 35 payments
  3. Novo Nordisk Inc $832 46 payments
  4. AbbVie, Inc. $831 25 payments
  5. Lilly USA, LLC $781 25 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $444 23 payments
  7. Amarin Pharma Inc. $380 20 payments
  8. GlaxoSmithKline, LLC. $322 7 payments
  9. Pfizer Inc. $271 15 payments
  10. Janssen Pharmaceuticals, Inc $247 9 payments
  11. Other $2,268 98 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,454 328 payments
  2. Education $1 1 payment
Products named General payments · program years 2019–2025
  1. FARXIGA $1,392 17 payments
  2. UBRELVY $630 20 payments
  3. Ozempic $626 39 payments
  4. BREZTRI $575 8 payments
  5. XIFAXAN $444 23 payments
  6. Repatha $426 19 payments
  7. EVENITY $385 8 payments
  8. Vascepa $380 20 payments
  9. RYBELSUS $372 32 payments
  10. AIMOVIG $309 13 payments
  11. Other $5,499 225 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

329 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other General Practice in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record